Slingshot members are tracking this event:
Alere HIV Combo Test Receives WHO Prequalification
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
“We can’t meet UNAIDS’ 90-90-90 target unless we achieve the first goal of ensuring that people with HIV know their status, and this requires helping healthcare workers in developing countries make every testing opportunity count,” said Collins Odhiambo, Ph.D., who evaluated the Alere HIV Combo at the Kenya Medical Research Institute (KEMRI). “The Alere HIV Combo brings point-of-care diagnosis directly to people at greatest risk for infection – including those in remote areas – and makes screenings as impactful as possible by enabling healthcare workers to identify highly infectious individuals, and link them to treatment.”
Slingshot Insights Explained
Jul 13, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Hiv Combo, Hiv-1 P24 Antigen